María S. Soengas

This paper identifies Midkine as a factor that disrupts melanoma dormancy by suppressing NR2F1 and altering signaling pathways, showing that targeting both Midkine and NR2F1 can limit metastasis and extend survival in mouse models.

This study identifies MIF as a key immunosuppressive factor in neuroblastoma that inhibits CAR T-cell efficacy, showing that blocking MIF enhances T-cell activation and therapeutic potential.